Novel serum paraoxonase activity assays are associated with coronary artery disease

Clinical Chemistry and Laboratory Medicine

Volumn 47, Issue 4, 2009, Pages 432-440

  Martinelli, Nicola ^a   Girelli, Domenico ^a   Olivieri, Oliviero ^a   Guarini, Patrizia ^a   Bassi, Antonella ^a   Trabetti, Elisabetta ^a   Friso, Simonetta ^a   Pizzolo, Francesca ^a   Bozzini, Claudia ^a   Tenuti, Ilaria ^a   Annarumma, Laura ^a   Schiavon, Renzo ^b   Franco Pignatti, Pier ^a   Corrocher, Roberto ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b Legnago General Hospital   (Italy)

Author keywords

Coronary artery disease; DEPCyMCase activity; Serum paraoxonase; TBBLase activity

Indexed keywords

ARYLDIALKYLPHOSPHATASE;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ARYLDIALKYLPHOSPHATASE; CORONARY ARTERY DISEASE; FEMALE; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; RISK FACTORS;

EID: 63849176055     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2009.108     Document Type: Article

References (41)

1. James RW. A long and winding road: defining the biological role and clinical importance of paraoxonases. Clin Chem Lab Med 2006;44:1052-9.
2. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991;286:152-4.
3. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998;394:284-7.
4. Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD, et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol 2000;20:2441-7.
5. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001; 21:1451-7.
6. Jarvik GP, Hatsukami TS, Carlson C, Richter RJ, Jampsa R, Brophy VH, et al. Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler Thromb Vasc Biol 2003;23:1465-71.
7. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M, et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 2003;107:2775-9.
8. Uzun H, Karter Y, Aydin S, Curgunlu A, Simsek G, Yucel R, et al. Oxidative stress in white coat hypertension; role of paraoxonase. J Hum Hypertens 2004;18:523-8.
9. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 1995;15:1812-8.
10. Sakai T, Matsuura B, Onji M. Serum paraoxonase activity and genotype distribution in Japanese patients with diabetes mellitus. Intern Med 1998;37:581-4.
11. Boemi M, Leviev I, Sirolla C, Pieri C, Marra M, James RW. Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis 2001;155:229-35.
12. Senti M, Tomas M, Fito M, Weinbrenner T, Covas MI, Sala J, et al. Antioxidant paraoxonase 1 activity in the metabolic syndrome. J Clin Endocrinol Metab 2003;88: 5422-6.
13. Blatter Garin MC, Kalix B, Morabia A, James RW. Small, dense lipoprotein particles and reduced paraoxonase-1 in patients with the metabolic syndrome. J Clin Endocrinol Metab 2005;90:2264-9.
14. Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M, et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991;86:193-9.
15. Martinelli N, Girelli D, Olivieri O, Stranieri C, Trabetti E, Pizzolo F, et al. Interaction between smoking and PON2 Ser311Cys polymorphism as a determinant of the risk of myocardial infarction. Eur J Clin Invest 2004;34:14-20.
16. Martinelli N, Girelli D, Olivieri O, Cavallari U, Biscuola M, Trabetti E, et al. Interaction between metabolic syndrome and PON1 polymorphisms as a determinant of the risk of coronary artery disease. Clin Exp Med 2005; 5:20-30.
17. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 2004;363:689-95.
18. Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky O, Meged R, et al. Structure and evolution of the serum paraoxonase family of detoxifying and antiatherosclerotic enzymes. Nat Struct Mol Biol 2004;11: 412-9.
19. Khersonsky O, Tawfik DS. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 2005;44:6371-82.
20. Khersonsky O, Tawfik DS. The histidine 115-histidine 134 dyad mediates the lactonase activity of mammalian serum paraoxonases. J Biol Chem 2006;281:7649-56.
21. Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 2005;46:1239-47.
22. Gaidukov L, Tawfik DS. High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I. Biochemistry 2005;44:11843-54.
23. Rosenblat M, Gaidukov L, Khersonsky O, Vaya J, Oren R, Tawfik DS, et al. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J Biol Chem 2006;281:7657-65.
24. Gaidukov L, Tawfik DS. The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity. J Lipid Res 2007;48:1637-46.
25. Khersonsky O, Tawfik DS. Chromogenic and fluorogenic assays for the lactonase activity of serum paraoxonases. Chembiochem 2006;7:49-53.
26. Girelli D, Russo C, Ferraresi P, Olivieri O, Pinotti M, Friso S, et al. Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. N Engl J Med 2000;343:774-80.
27. Olivieri O, Martinelli N, Sandri M, Bassi A, Guarini P, Trabetti E, et al. Apolipoprotein C-III, n-3 polyunsaturated fatty acids, and "insulin-resistant" T-455C APOC3 gene polymorphism in heart disease patients: example of gene-diet interaction. Clin Chem 2005;51:360-7.
28. Cheng S, Grow MA, Pallaud C, Klitz W, Erlich HA, Visvikis S, et al. A multilocus genotyping assay for candidate markers of cardiovascular disease risk. Genome Res 1999;9:936-49.
29. Rozek LS, Hatsukami TS, Richter RJ, Ranchalis J, Nakayama K, McKinstry LA, et al. The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status. J Lipid Res 2005;46:1888-95.
30. Blatter Garin MC, Moren X, James RW. Paraoxonase-1 and serum concentrations of HDL-cholesterol and apoAI. J Lipid Res 2006;47:515-20.
31. Brinton EA, Eisenberg S, Breslow JL. Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. Arterioscler Thromb 1994;14:707-20.
32. Deakin S, Leviev I, Guernier S, James RW. Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory elementbinding protein-2. Arterioscler Thromb Vasc Biol 2003; 23:2083-9.
33. Miserez AR, Muller PY, Barella L, Barella S, Staehelin HB, Leitersdorf E, et al. Sterol-regulatory element-binding protein (SREBP)-2 contributes to polygenic hypercholesterolaemia. Atherosclerosis 2002;164:15-26.
34. Rodriguez C, Raposo B, Martinez-Gonzalez J, Llorente-Cortes V, Vilahur G, Badimon L. Modulation of ERG25 expression by LDL in vascular cells. Cardiovasc Res 2003;58:178-85.
35. Duan X, Zhu W, Li Y, Zhang Z, Zhao Y, Dao J, et al. The effect of sterol regulatory element-binding protein 2 polymorphism on the serum lipid in northern Chinese subjects. J Lipid Res 2005;46:252-7.
36. Gaidukov L, Rosenblat M, Aviram M, Tawfik DS. The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux. J Lipid Res 2006;47:2492-502.
37. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 1999;26: 892-904.
38. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 1999;19:330-5.
39. Domagala TB, Lacinski M, Trzeciak WH, Mackness B, Mackness MI, Jakubowski H. The correlation of homocysteine-thiolactonase activity of the paraoxonase (PON1) protein with coronary heart disease status. Cell Mol Biol (Noisy-le-grand) 2006;52:4-10.
40. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007;117:746-56.
41. Vekic J, Kotur-Stevuljevic J, Jelic-Ivanovic Z, Spasic S, Spasojevic-Kalimanovska V, Topic A, et al. Association of oxidative stress and PON1 with LDL and HDL particle size in middle-aged subjects. Eur J Clin Invest 2007;37: 715-23.